January 2011- Volume 7, Issue 1

January 2011

In this Issue

Global News

A star is born

A star is born

Boehringer Ingelheim draws a bead on multiple antibody targets and therapeutic areas in a collaboration with Austria’s f-star

From courtship to formal engagement

From courtship to formal engagement

After months of talking and speculation, Johnson & Johnson makes official its $2.3 billion bid to acquire Dutch biotech Crucell

Thermo turns up heat on Asia-Pacific expansion plans

Thermo turns up heat on Asia-Pacific expansion plans

Company plans to acquire Dionex Corp. for $2.1 billion and Lomb Scientific for undisclosed sum

A lot to digest

A lot to digest

Axcan gobbles up Eurand for almost $600 million

Companies converge on pain

Companies converge on pain

UK’s Convergence Pharmaceuticals, Selcia join forces to develop new drugs for chronic pain

Government Watch

Wherever you go (online), there the sales pitches are

Wherever you go (online), there the sales pitches are

Healthcare marketing on the Internet draws interest from privacy groups

Stem cell case makes its way through courts

Stem cell case makes its way through courts

Contentious case could be in for long haul as attorneys for both sides make arguments to appellate court

Throw the biotech baby out with the bath water?

Throw the biotech baby out with the bath water?

U.S. Department of Justice files precedent-setting amicus curiae brief in landmark DNA patent case

Compare and contrast

Compare and contrast

As U.S. regulators look to implement a regulatory pathway for biosimilars, Brookings Institute panel shares lessons learned from other countries’ experience

Research & Development

Merck plays it smart

Merck plays it smart

Pharma acquires SmartCells and a unique preclinical insulin injection program for more than $500 million

Extending its reach

Extending its reach

EHSI acquires stem cell biotech firm Celulas Genetica

Breaking through the barrier

Breaking through the barrier

Geron licenses peptide from Angiochem to help get cancer therapeutics past the blood-brain barrier

Baxter’s buying

Baxter’s buying

After dropping generic injectables, company adds hemophilia-related assets of Archemix to product stable

Diagnostics

An Avid acquisition

An Avid acquisition

Lilly acquires Avid Radiopharmaceuticals for upfront payment of $300 million

In vitro to in vivo

In vitro to in vivo

Seeking to bridge gap between in-vitro assays and in-vivo results, Caliper acquires CRi for $20 million

Opportunity knocks

Opportunity knocks

Bio-Reference Laboratories joins with Massachusetts General Hospital to refine diagnostic tests, expand personalized medicine

Transgenomic Inc. acquires Clinical Data’s diagnostic unit

Transgenomic Inc. acquires Clinical Data’s diagnostic unit

Addition of high- growth business accelerates company’s expansion into molecular diagnostics

Creating biomarkers to strike disease early

Creating biomarkers to strike disease early

Ariana Pharma enters viral hepatitis partnership with Bio-Rad, Inserm and Beaujon Hospital

Roche inks several important diagnostic deals

Roche inks several important diagnostic deals

Roche announced that it signed three important collaboration deals in the diagnostic arena.

Editor's Focus

A positive image never goes out of style

A positive image never goes out of style

Plagued by the economic downturn, generic competition, sluggish innovation and concerns over drug safety and efficacy, the pharma and biotech industries in recent years have undergone serious makeovers in the form of cost-cutting, layoffs, reorganization, mergers and acquisitions—but are these industries putting their best faces forward?

Commentary

Oversaturation vs. tunnel vision

Oversaturation vs. tunnel vision

Pharma has a difficult balance between trying to tackle many targets and do well with the ones it already had to work on

Similar or not similar: That is the question

Similar or not similar: That is the question

Scientific hurdles face approval of biosimilars versus generics

Feature

Start of a new era

Start of a new era

Palm Springs plays host to the last distinct LabAutomation meeting as former ALA members look toward mingling with former SBS members in a single annual meeting in 2012

Omics & Systems Biology

Thinking and doing

Thinking and doing

Quintiles, London Genetics ink pharmacogenetic deal

Teaming up to fight Alzheimer’s

Teaming up to fight Alzheimer’s

GE Healthcare enters research collaboration with Janssen Pharmaceutica to identify biosignatures in Alzheimer’s disease detection

A pathway to the future

A pathway to the future

Active Motif acquires Genpathway for success in next era of next-gen sequencing

Persistence for resistance

Persistence for resistance

Canadian researchers use virtual screening to target prostate cancer receptor

Special Reports

Research at the speed of light

Research at the speed of light

High-throughput screening technology leads to advances in drug discovery

Billions of screens have produced … what?

Billions of screens have produced … what?

Critics of high-throughput screening ask: Is the approach of building a bigger haystack really the best way to find more needles?

Instruments & Informatics

Arriving at destination

Arriving at destination

Thomson Reuters acquires ‘GPS in pathway analysis’ GeneGo

Passing the screen(ing) test

Passing the screen(ing) test

DiscoveRx acquires KINOMEscan, creating largest portfolio of proprietary GPCR and kinase assays

Of standards and armored RNA

Of standards and armored RNA

Asuragen to collaborate with Novartis on the development of BCR-ABL1 RNA IS calibrators and laboratory software reporting tool

Sending the right signals

Sending the right signals

Activiomics signs technology agreement with UCB
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022